Anavex Receives European Medicines Agency Approval for Alzheimer’s Treatment Application
In December 2023, Anavex Life Sciences Corp., a biopharmaceutical company specializing in treatments for neurodegenerative and neurodevelopmental diseases, announced a significant milestone for its Alzheimer’s disease drug, blarcamesine. The Committee […]